These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 26277100)

  • 41. Outcome assessment for clinical trials: how many adjudicators do we need? Canadian Lung Oncology Group.
    Walter SD; Cook DJ; Guyatt GH; King D; Troyan S
    Control Clin Trials; 1997 Feb; 18(1):27-42. PubMed ID: 9055050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A new SPECT/CT reconstruction algorithm: reliability and accuracy in clinical routine for non-oncologic bone diseases.
    Delcroix O; Robin P; Gouillou M; Le Duc-Pennec A; Alavi Z; Le Roux PY; Abgral R; Salaun PY; Bourhis D; Querellou S
    EJNMMI Res; 2018 Feb; 8(1):14. PubMed ID: 29435671
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interobserver agreement: A preliminary investigation into how much is enough?
    Hausman NL; Javed N; Bednar MK; Guell M; Schaller E; Nevill RE; Kahng S
    J Appl Behav Anal; 2022 Mar; 55(2):357-368. PubMed ID: 33482012
    [TBL] [Abstract][Full Text] [Related]  

  • 44. When is a confirmatory randomized clinical trial needed?
    Berry DA
    J Natl Cancer Inst; 1996 Nov; 88(22):1606-7. PubMed ID: 8931598
    [No Abstract]   [Full Text] [Related]  

  • 45. [Lung cancer: what criteria are available to assess the post-treatment response?].
    Milleron B
    Rev Pneumol Clin; 2009 Apr; 65(2):123-6. PubMed ID: 19375054
    [No Abstract]   [Full Text] [Related]  

  • 46. WIDEN: A tool for medical image management in multicenter clinical trials.
    Chauvie S; Biggi A; Stancu A; Cerello P; Cavallo A; Fallanca F; Ficola U; Gregianin M; Guerra UP; Chiaravalloti A; Schillaci O; Gallamini A
    Clin Trials; 2014 Jun; 11(3):355-361. PubMed ID: 24711610
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathology review in cancer research.
    Freedman LS; Machin D
    Br J Cancer; 1993 Nov; 68(5):827-30. PubMed ID: 8217596
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Past, present and future of IOA from my eyes and mind.
    Raza H
    Indian J Orthop; 2008 Oct; 42(4):487-9. PubMed ID: 19753245
    [No Abstract]   [Full Text] [Related]  

  • 49. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
    Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
    Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interobserver Variability in Contouring Hepatocellular Carcinoma at a Tertiary Center.
    DE LA Pinta C; García JD; Sevillano D; Colmenares R; García Latorre R; Garví M; Pino V; Muriel A; Martín M; Fernández E; Hernanz R; Martín M; Domínguez JA; Muñóz T; Perna LC; Albillos A; Sancho S
    Cancer Diagn Progn; 2023; 3(4):433-438. PubMed ID: 37405211
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The clinical impact of observer variability in lung nodule classification in children with Wilms tumour.
    Brok JS; Shelmerdine S; Damsgaard F; Smets A; Irtan S; Swinson S; Hedayati V; Jacob J; Nair A; Oostveen M; Pritchard-Jones K; Olsen Ø
    Pediatr Blood Cancer; 2022 Oct; 69(10):e29759. PubMed ID: 35652617
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer.
    Rodríguez De Dios N; Navarro-Martin A; Cigarral C; Chicas-Sett R; García R; Garcia V; Gonzalez JA; Gonzalo S; Murcia-Mejía M; Robaina R; Sotoca A; Vallejo C; Valtueña G; Couñago F
    World J Clin Oncol; 2022 Apr; 13(4):237-266. PubMed ID: 35582651
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[
    Vaz SC; Adam JA; Delgado Bolton RC; Vera P; van Elmpt W; Herrmann K; Hicks RJ; Lievens Y; Santos A; Schöder H; Dubray B; Visvikis D; Troost EGC; de Geus-Oei LF
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1386-1406. PubMed ID: 35022844
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evolving target volume concepts in locally advanced non-small cell lung cancer.
    Nestle U; Le Pechoux C; De Ruysscher D
    Transl Lung Cancer Res; 2021 Apr; 10(4):1999-2010. PubMed ID: 34012809
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
    Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization.
    MacManus M; Everitt S; Schimek-Jasch T; Li XA; Nestle U; Kong FS
    Transl Lung Cancer Res; 2017 Dec; 6(6):670-688. PubMed ID: 29218270
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interobserver variability in target volume delineation of hepatocellular carcinoma : An analysis of the working group "Stereotactic Radiotherapy" of the German Society for Radiation Oncology (DEGRO).
    Gkika E; Tanadini-Lang S; Kirste S; Holzner PA; Neeff HP; Rischke HC; Reese T; Lohaus F; Duma MN; Dieckmann K; Semrau R; Stockinger M; Imhoff D; Kremers N; Häfner MF; Andratschke N; Nestle U; Grosu AL; Guckenberger M; Brunner TB
    Strahlenther Onkol; 2017 Oct; 193(10):823-830. PubMed ID: 28695316
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved inter-observer agreement of an expert review panel in an oncology treatment trial--Insights from a structured interventional process.
    Nestle U; Rischke HC; Eschmann SM; Holl G; Tosch M; Miederer M; Plotkin M; Essler M; Puskas C; Schimek-Jasch T; Duncker-Rohr V; Rühl F; Leifert A; Mix M; Grosu AL; König J; Vach W
    Eur J Cancer; 2015 Nov; 51(17):2525-33. PubMed ID: 26277100
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort.
    Brose A; Michalski K; Ruf J; Tosch M; Eschmann SM; Schreckenberger M; König J; Nestle U; Miederer M
    Cancer Imaging; 2023 May; 23(1):45. PubMed ID: 37198668
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.